Brazil May Be Emerging Market Darling, But Surprises Await Pharmas
This article was originally published in PharmAsia News
Brazil is seen increasingly as the next big emerging market for drug makers, but they may find difficulty in navigating the nation's often confusing and complex business system.
You may also be interested in...
The sentences are the latest chapter in a long-running off-label marketing case.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.